
    
      Maximum estimated study duration per patient: either 27 weeks (patients randomized to insulin
      glargine arm) or 51 weeks (patients randomized to liraglutide arm) broken down as follow:

        -  A 2-week of screening period,

        -  A 24-week comparative period,

        -  A 24-week extension period (only for patients treated with liraglutide, not adequately
           controlled at the end of the comparative period),

        -  A 1-week follow-up period
    
  